Literature DB >> 21983205

CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole.

Matilde Yáñez1, Lucía Galán, Jorge Matías-Guiu, Alvaro Vela, Antonio Guerrero, Antonio G García.   

Abstract

The neurotoxic effects of cerebrospinal fluid (CSF) from patients suffering amyotrophic lateral sclerosis (ALS), have been reported by various authors. However, variable results have been communicated and the mechanism of such neurotoxicity has been attributed to excess glutamate concentrations in ALS/CSF. We have studied here the properties of 14 CSFs from control patients and 29 CSFs from patients of ALS. We found that while ALS/CSF impairs the viability of rat brain cortical motoneurons maintained in primary cultures, this effect seemed to be exerted through a glutamate-independent mechanism. Resveratrol protected against such neurotoxic effects and antagonized the [Ca(+2)](c) elevation produced by ALS/CSF. However, riluzole did not afford protection and antagonized the resveratrol-elicited neuroprotective effects. We conclude that ALS/CSF elicited neurotoxicity on in vitro cultures of rat brain cortical motor neurons may become a sound microassay to test available novel multitargeted neuroprotective compounds with potential therapeutic application in ALS patients.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983205     DOI: 10.1016/j.brainres.2011.09.025

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

Review 1.  The brain, sirtuins, and ageing.

Authors:  Akiko Satoh; Shin-Ichiro Imai; Leonard Guarente
Journal:  Nat Rev Neurosci       Date:  2017-05-18       Impact factor: 34.870

Review 2.  SIRT1 in neurodevelopment and brain senescence.

Authors:  A Zara Herskovits; Leonard Guarente
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

3.  Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice.

Authors:  Renzo Mancuso; Jaume del Valle; Laura Modol; Anna Martinez; Ana B Granado-Serrano; Omar Ramirez-Núñez; Mercé Pallás; Manel Portero-Otin; Rosario Osta; Xavier Navarro
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 4.  Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Lucas T Vu; Robert Bowser
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 5.  Calcium dysregulation and neuroinflammation: discrete and integrated mechanisms for age-related synaptic dysfunction.

Authors:  Diana M Sama; Christopher M Norris
Journal:  Ageing Res Rev       Date:  2013-06-08       Impact factor: 10.895

Review 6.  Resveratrol: A Focus on Several Neurodegenerative Diseases.

Authors:  Ester Tellone; Antonio Galtieri; Annamaria Russo; Bruno Giardina; Silvana Ficarra
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

7.  Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates.

Authors:  Francisco J Romero Durán; Nerea Alonso; Olga Caamaño; Xerardo García-Mera; Matilde Yañez; Francisco J Prado-Prado; Humberto González-Díaz
Journal:  Int J Mol Sci       Date:  2014-09-24       Impact factor: 5.923

8.  Exposure to ALS-FTD-CSF generates TDP-43 aggregates in glioblastoma cells through exosomes and TNTs-like structure.

Authors:  Xuebing Ding; Mingming Ma; Junfang Teng; Robert K F Teng; Shuang Zhou; Jingzheng Yin; Ekokobe Fonkem; Jason H Huang; Erxi Wu; Xuejing Wang
Journal:  Oncotarget       Date:  2015-09-15

Review 9.  Sirtuin deacetylases in neurodegenerative diseases of aging.

Authors:  Adrianna Z Herskovits; Leonard Guarente
Journal:  Cell Res       Date:  2013-05-21       Impact factor: 25.617

Review 10.  Sirtuin deacetylases as therapeutic targets in the nervous system.

Authors:  Brett Langley; Anthony Sauve
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.